In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Protalix BioTherapeutics Inc. (AMEX: PLX) closed at $1.11 down -2.63% from its previous closing price of $1.14. In other words, the price has decreased by -$2.63 from its previous closing price. On the day, 1.01 million shares were traded. PLX stock price reached its highest trading level at $1.16 during the session, while it also had its lowest trading level at $1.07.
Ratios:
For a deeper understanding of Protalix BioTherapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 19 ’23 when Bashan Dror bought 64,516 shares for $1.40 per share. The transaction valued at 90,484 led to the insider holds 132,516 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 83279408 and an Enterprise Value of 62808856. As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.92, and their Forward P/E ratio for the next fiscal year is 1.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.24 while its Price-to-Book (P/B) ratio in mrq is 2.41. Its current Enterprise Value per Revenue stands at 0.959 whereas that against EBITDA is 5.391.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $3.55, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -14.90%, while the 200-Day Moving Average is calculated to be -28.46%.
Shares Statistics:
For the past three months, PLX has traded an average of 370.15K shares per day and 373420 over the past ten days. A total of 72.95M shares are outstanding, with a floating share count of 62.72M. Insiders hold about 14.46% of the company’s shares, while institutions hold 13.69% stake in the company. Shares short for PLX as of 1713139200 were 6703631 with a Short Ratio of 18.11, compared to 1710460800 on 6674487. Therefore, it implies a Short% of Shares Outstanding of 6703631 and a Short% of Float of 9.43.
